[
    {
        "@id": "http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps#assertion",
        "@graph": [
            {
                "@id": "http://purl.obolibrary.org/obo/MONDO_0024612",
                "https://w3id.org/biolink/vocab/category": [
                    {
                        "@id": "https://w3id.org/biolink/vocab/Disease"
                    }
                ]
            },
            {
                "@id": "http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps#association",
                "http://www.w3.org/1999/02/22-rdf-syntax-ns#object": [
                    {
                        "@id": "http://purl.obolibrary.org/obo/MONDO_0024612"
                    }
                ],
                "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate": [
                    {
                        "@id": "https://w3id.org/biolink/vocab/treats"
                    }
                ],
                "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject": [
                    {
                        "@id": "https://identifiers.org/DRUGBANK:DB01267"
                    }
                ],
                "@type": [
                    "http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement"
                ],
                "http://www.w3.org/2000/01/rdf-schema#label": [
                    {
                        "@value": "Paliperidone is FDA-approved for schizophrenia aged 12-17. However, the pharmacologic portfolio, extrapolation from adult studies, and the long track record of the parent drug, risperidone in child/adolescent psychiatric (CAP) population might expand its therapeutic potential. An 8-week open-label study [9] examined paliperidone monotherapy for acute mania, mixed, or hypomanic episode in pediatric patients (n = 15, 6–17 years of age) with bipolar spectrum disorders. At the end of follow-up period, 11 subjects (73%) completed the study; treatment with paliperidone was associated with a 60% response rate (50% decrease in the Young Mania Rating Scale) and 40% remission (YMRS <12)"
                    }
                ],
                "https://w3id.org/biolink/vocab/provided_by": [
                    {
                        "@id": "https://w3id.org/um/NeuroDKG"
                    }
                ],
                "https://w3id.org/biolink/vocab/publications": [
                    {
                        "@id": "https://pubmed.ncbi.nlm.nih.gov/31096228"
                    }
                ],
                "https://w3id.org/biolink/vocab/relation": [
                    {
                        "@id": "https://w3id.org/um/neurodkg/OffLabelIndication"
                    }
                ]
            },
            {
                "@id": "https://identifiers.org/DRUGBANK:DB01267",
                "https://w3id.org/biolink/vocab/category": [
                    {
                        "@id": "https://w3id.org/biolink/vocab/Drug"
                    }
                ]
            }
        ]
    },
    {
        "@id": "http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps#Head",
        "@graph": [
            {
                "@id": "http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps",
                "http://www.nanopub.org/nschema#hasAssertion": [
                    {
                        "@id": "http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps#assertion"
                    }
                ],
                "http://www.nanopub.org/nschema#hasProvenance": [
                    {
                        "@id": "http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps#provenance"
                    }
                ],
                "http://www.nanopub.org/nschema#hasPublicationInfo": [
                    {
                        "@id": "http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps#pubinfo"
                    }
                ],
                "@type": [
                    "http://www.nanopub.org/nschema#Nanopublication"
                ]
            }
        ]
    },
    {
        "@id": "http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps#pubinfo",
        "@graph": [
            {
                "@id": "http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps#sig",
                "http://purl.org/nanopub/x/hasAlgorithm": [
                    {
                        "@value": "RSA"
                    }
                ],
                "http://purl.org/nanopub/x/hasPublicKey": [
                    {
                        "@value": "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCamPJb4SzqpLXn//XJ5dlVfzz6QI+RPmiJTLXF/by2JR7sHMKRsCQDFsYMlq8zGHghOIkjRP9dpLZUtZzUcHt3MXiFKEPo8eGzUe9p+JXKFC8xxkJr94z2vq6IdMf71Iu1GH8SeDAKt/DgYO4zNaw8VuXvxnZRewKZSA+u8zWPVwIDAQAB"
                    }
                ],
                "http://purl.org/nanopub/x/hasSignature": [
                    {
                        "@value": "S36lxqMhE/il6hZ0x3opIf+BSGkgmrLS42CchAvMGjt03GhGQT20XdwHEBLps4EIevPEFYR3JCJttJowJ3HtWv4hSQ5sLxtGzcLW+7AD86Mrp/G3xGClqtMyQmf0MU7glLc83g8n8nenTaQOX37aaSuUPH+I3cZQJ1cSqTfX5ss="
                    }
                ],
                "http://purl.org/nanopub/x/hasSignatureTarget": [
                    {
                        "@id": "http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps"
                    }
                ]
            },
            {
                "@id": "http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps",
                "http://purl.org/dc/terms/created": [
                    {
                        "@value": "2021-09-13T13:11:54.555+02:00",
                        "@type": "http://www.w3.org/2001/XMLSchema#dateTime"
                    }
                ],
                "http://purl.org/dc/terms/creator": [
                    {
                        "@id": "https://orcid.org/0000-0002-7641-6446"
                    }
                ],
                "http://purl.org/nanopub/x/supersedes": [
                    {
                        "@id": "http://purl.org/np/RA5i91jVBRKHpwDOPIiWGzt3c3Rs8wAqKRXxOYhegMxOI"
                    }
                ],
                "http://www.w3.org/ns/prov#generatedAtTime": [
                    {
                        "@value": "2021-08-24T15:53:47.29208"
                    }
                ],
                "http://www.w3.org/ns/prov#wasAttributedTo": [
                    {
                        "@id": "https://orcid.org/0000-0002-7641-6446"
                    }
                ],
                "https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate": [
                    {
                        "@id": "http://purl.org/np/RAcm8OurwUk15WOgBM9wySo-T3a5h6as4K8YR5MBrrxUc"
                    }
                ],
                "https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate": [
                    {
                        "@id": "http://purl.org/np/RA2vCBXZf-icEcVRGhulJXugTGxpsV5yVr9yqCI1bQh4A"
                    },
                    {
                        "@id": "http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM"
                    },
                    {
                        "@id": "http://purl.org/np/RAjpBMlw3owYhJUBo3DtsuDlXsNAJ8cnGeWAutDVjuAuI"
                    }
                ],
                "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate": [
                    {
                        "@id": "http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY"
                    }
                ]
            }
        ]
    },
    {
        "@id": "http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps#provenance",
        "@graph": [
            {
                "@id": "http://purl.org/np/RAW5kVwsRJ39K39wCgY5vvF6ha59l1ji00G_ZMV03HBps#assertion",
                "http://www.w3.org/ns/prov#generatedAtTime": [
                    {
                        "@value": "2021-08-24T15:53:47.29208"
                    }
                ]
            }
        ]
    }
]